Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...
Elanco Animal Health Inc (ELAN) reports robust organic growth and significant debt reduction, setting a positive outlook for ...
Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...
Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...
Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...
Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.
Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...
Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.
Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.
Elanco Animal Health (NYSE:ELAN) traded lower in the premarket on Tuesday after the veterinary product maker, with its Q4 2024 results, set its full-year outlook below consensus, citing an unfavorable ...
Elanco Animal Health (NYSE:ELAN – Get Free Report) is anticipated to announce its earnings results before the market opens on ...
Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.